Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
RAB38
is a new member of the RAB small G protein family that regulates intracellular vesicle trafficking.
RAB38
is expressed in melanocytes and it has been shown that a point mutation in the postulated GTP-binding domain of
RAB38
is the gene responsible for human Hermansky-Pudlak syndrome. However, the prognostic and molecular features of tumors with
RAB38
expression is still unclear, as well as
glioma
. Whole genome mRNA expression microarray data on 220
glioma
samples from the Chinese
glioma
genome atlas (CGGA) database (http://www.cgga.org.cn) was applied as discovery set. Each grade of
glioma
patients was analyzed by the Kaplan-Meier method. To determine the protein expression levels of
RAB38
, further 82
glioma
tissues were stained by immunohistochemistry. Three additional datasets (TCGA, GSE16011 and Rembrandt) were obtained as validation sets. The functional annotation of
RAB38
was analyzed by Gene ontology (GO) analysis and Gene set variation analysis (GSVA) in 89 glioblastomas (GBMs). High
RAB38
expression was mainly increased in high-grade gliomas, and high
RAB38
expression also conferred high mortality of
glioma
in the CGGA cohort.
RAB38
showed a mesenchymal subtype, G3 subtype and isocitrate dehydrogenase 1 (IDH1) wild-type preference. GO and GSVA analysis showed that
RAB38
was significantly correlated with migration. These results were validated in other 3 datasets. The expression levels of
RAB38
were significantly associated with grade progression as well as prognosis in gliomas.
RAB38
is an important prognostic biomarker and potential therapeutic target in gliomas.
...
PMID:RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma. 2402 99